Much controversy remains over the use of laetrile in the treatment of leukemia. Public opinion has been responsible for several state legislatures enacting bills allowing the use of laetrile for patients with leukemia and other malignancies. We recently cared for a 3½-year-old child with acute lympho blastic leukemia, who had low initial white blood cell count, limited organo megaly, and absence of T or B cell markers. A good prognosis was anticipated. Conventional therapy was interrupted for long periods of time with laetrile. Laetrile was ineffective in maintaining or inducing remission. Despite favor able prognosis, the child developed several relapses and died with widespread infiltration of leukemia in the central nervous system, bone marrow and viscera.
Get full access to this article
View all access options for this article.
References
1.
United States Department of Health, Education and Welfare: Laetrile: commissioner's decision on status. Fed Register42:39768, 1977
2.
Dorr RT, Paxinos J.: The current status of laetrile. Ann Intern Med89:389, 1978
3.
Smith FP, Butler TP, Cohan S., et al: Laetrile toxicity: a report of two patients. Cancer Treat Rep62:169, 1978
4.
Lewis JP: Laetrile. West J Med127:55, 1977
5.
Catovsky D., Galton DA: Cell markers and the classification of acute leukemias. Haematol BloodTransfusion20:25, 1977
6.
George S., Fernbach DJ, Vietti TJ, et al: Factors influencing survival in pediatric acute leukemia. The SWCCSG experience 1958-1970. Cancer32:1542, 1973
7.
Khandekar JD , Edelman H.: Studies of amygdalin (laetrile) toxicity in rodents. JAMA242:169, 1979
8.
Schmidt ES, Newton GW, Sanders SM, et al: Laetrile toxicity studies in dogs. JAMA239:943, 1978
